MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.msard.2026.107380

Медицинская библиотека · Multiple sclerosis and related disorders · 2026

Executive Summary of the Malaysian consensus statements for the diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD).

Viswanathan Shanthi, Arip Masita, Abdullah Suhailah, Hiew Fu Liong, Wong Chun Hoong, Sahadevan Mahavishnu, Krishnan Dhayalen, Chew Sin Hong, Hung Stefanie Kar Yan, Chey Shin Yee, Kok Huey Tean, Gan Kai Xin, Rajah Rathika, Mohamad Siti Mardhiana, Choong King Yen, Abdul Wahab Asrul, Abdullah Siti Fatimah, Abas Buang Zulkifli, Hor Pei Zhi, Low Seow Huey, Santok Singh Kamal Preet Kaur, Lee Richearn

СтатьяПеревод в очереди

Аннотация

Neuromyelitis optica spectrum disorder (NMOSD) is a rare immune-mediated astrocytopathy associated with recurrent inflammatory attacks of the central nervous system and substantial morbidity if not diagnosed and treated promptly. This Executive Summary presents the key recommendations and summary of the supporting evidence from the Malaysian Consensus Statements for the Diagnosis and Management of NMOSD. A modified Delphi methodology involving a multidisciplinary panel from public and private healthcare institutions was employed. Consensus statements were developed through structured discussions, iterative review, and three rounds of anonymous voting with a predefined agreement threshold of 75%. Subsequent refinement included supplementary considerations for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and double-seronegative NMOSD. International evidence and guideline recommendations were contextualised to reflect Malaysian clinical practice and healthcare resource considerations. The final consensus comprised 36 statements across 9 domains, with an additional 3 supplementary statements relating to MOGAD and double-seronegative NMOSD. It addressed diagnosis, treatment selection, relapse management, biologic monitoring, vaccination, and biologic use in special populations. The recommendations emphasise the continued use of established diagnostic criteria and highlight the central role of aquaporin-4 immunoglobulin G (AQP4-IgG) serostatus for diagnosis and therapeutic decisions. Approved biologic therapies are supported for AQP4-IgG-seropositive NMOSD, with guidance provided for the use of off-label immunosuppression in resource-variable settings. These Malaysian consensus statements provide a practical and locally relevant framework to support more consistent and evidence-based NMOSD care. The full consensus document and detailed evidence summaries are available online via the Malaysian Society of Neurosciences website.

Для цитирования: Viswanathan Shanthi, Arip Masita, Abdullah Suhailah, Hiew Fu Liong, Wong Chun Hoong, Sahadevan Mahavishnu, Krishnan Dhayalen, Chew Sin Hong, Hung Stefanie Kar Yan, Chey Shin Yee, Kok Huey Tean, Gan Kai Xin, Rajah Rathika, Mohamad Siti Mardhiana, Choong King Yen, Abdul Wahab Asrul, Abdullah Siti Fatimah, Abas Buang Zulkifli, Hor Pei Zhi, Low Seow Huey, Santok Singh Kamal Preet Kaur, Lee Richearn. Executive Summary of the Malaysian consensus statements for the diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD).. Multiple sclerosis and related disorders. 2026. DOI: 10.1016/j.msard.2026.107380.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.